Nicholas Kitchin

ORCID

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 5

Top Venues

Vaccines

This page only lists publications with an associated author ORCID identifier.

Publications

Juleen Gayed, Vishva Bangad, Xia Xu, Federico Mensa, Mark Cutler, Özlem Türeci, Uǧur Şahin, Kayvon Modjarrad, Kena A Swanson, Annaliesa S Anderson, Alejandra Gurtman, Nicholas Kitchin, null null
Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine against XBB.1.5, BA.2.86, and JN.1 Sublineages: A Phase 2/3 Trial. Vaccines 12 (7) (2024)
Juleen Gayed, Vishva Bangad, Xia Xu, Federico Mensa, Mark Cutler, Özlem Türeci, Uǧur Şahin, Kayvon Modjarrad, Kena A Swanson, Annaliesa S Anderson, Alejandra Gurtman, Nicholas Kitchin, null null
Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine against XBB.1.5, BA.2.86, and JN.1 Sublineages: A Phase 2/3 Trial. Vaccines 12 (7) (2024)
Juleen Gayed, Oyeniyi Diya, Francine S Lowry, Xia Xu, Vishva Bangad, Federico Mensa, Jing Zou, Xuping Xie, Yanping Hu, Claire Lu, Mark Cutler, Todd Belanger, David Cooper, Kenneth Koury, Annaliesa S Anderson, Özlem Türeci, Uǧur Şahin, Kena A Swanson, Kayvon Modjarrad, Alejandra Gurtman, Nicholas Kitchin, null null
Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial. Vaccines 12 (2) (2024)
Juleen Gayed, Vishva Bangad, Xia Xu, Federico Mensa, Mark Cutler, Özlem Türeci, Uǧur Şahin, Kayvon Modjarrad, Kena A Swanson, Annaliesa S Anderson, Alejandra Gurtman, Nicholas Kitchin, null null
Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine against XBB.1.5, BA.2.86, and JN.1 Sublineages: A Phase 2/3 Trial. Vaccines 12 (7) (2024)
Juleen Gayed, Oyeniyi Diya, Francine S Lowry, Xia Xu, Vishva Bangad, Federico Mensa, Jing Zou, Xuping Xie, Yanping Hu, Claire Lu, Mark Cutler, Todd Belanger, David Cooper, Kenneth Koury, Annaliesa S Anderson, Özlem Türeci, Uǧur Şahin, Kena A Swanson, Kayvon Modjarrad, Alejandra Gurtman, Nicholas Kitchin, null null
Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial. Vaccines 12 (2) (2024)

Nicholas Kitchin.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Nicholas Kitchin